18-FDG imaging in breast cancer

Seminars in Nuclear Medicine

Volumn 29, Issue 1, 1999, Pages 49-56

  Hoh, C K ^a   Schiepers, C ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER SCREENING; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 0032890675     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(99)80029-4     Document Type: Article

References (35)

1. Parker SL Tong T Bolden S Wingo PA Cancer Statistics 1997 CAA Cancer J Clin 47 1997 5 27
2. Minn H Soini I [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer Eur J Nucl Med 15 1989 61 66
3. Wahl RL Cody R Hutchins GD Mudgett E Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabelled glucose analog 2-(F-18)-fluoro-deoxy-2-D-glucose (FDG) Radiology 179 1991 765 770
4. Tse NY Hoh CK Hawkins RA The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease Ann Surg 216 1992 27 34
5. Nieweg OE Kim EE Wong WH Broussard WF Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer Cancer 71 1993 3920 3925
6. Crowe JP Jr Adler LP Shenk RR Sunshine J Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings Ann Surg Onc 1 1994 132 140
7. Dehdashti F Mortimer JE Siegel BA Griffeth LK Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays J Nucl Med 36 1995 1766 1774
8. Holle LH Trampert L Lung-Kurt S Villena-Heinsen CE Investigations of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT J Nucl Med 37 1996 615 622
9. Avril N Dose J Janicke F Bense S Ziegler S Laubenbacher C Romer W Pache H Herz M Allgayer B Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose J Clin Onc 14 1996 1848 1857
10. Scheidhauer K Scharl A Pietrzyk U Wagner R Gohring UJ Schomacker K Schicha H Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability Eur J Nucl Med 23 1996 618 623
11. Kole AC Nieweg OE Pruim J Paans AM Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1–11C]tyrosine PET J Nucl Med 38 1997 692 696
12. Avril N Bense S Ziegler SI Dose J Weber W Laubenbacher C Romer W Janicke F Schwaiger M Breast imaging with fluorine-18-FDG PET: quantitative image analysis J Nucl Med 38 1997 1186 1191
13. Rosen PP Groshen S Saigo PE Kinne DW A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma J Clin Oncol 7 1989 355 366
14. Rosen PP Groshen S Saigo PE Kinne DW Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years J Clin Oncol 7 1989 1239 1251
15. Wahl RL Helvie MA Chang AE Anderson I Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET J Nucl Med 35 1994 872 875
16. Palmedo H Bender H Grunwald F Mallmann P Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours Eur J Nucl Med 24 1997 1138 1145
17. Stavros AT Thickman D Rapp CL Dennis MA Solid breast nodules: use of sonography to distinguish between benign and malignant lesions Radiology 196 1995 123 124
18. Wahl RL Kamiski MS Ethier SP Hutchins GD The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes J Nucl Med 31 1990 1831 1835
19. Adler LP Crowe JP al-Kaisi NK Sunshine JL Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET Radiology 187 1993 743 750
20. Avril N Dose J Janicke F Ziegler S Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose J Nat Can Inst 88 1996 1204 1209
21. Utech CI Young CS Winter PF Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry Eur J Nucl Med 23 1996 1588 1593
22. Adler LP Faulhaber PF Schnur KC Al-Kasi NL Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET Radiology 203 1997 323 327
23. Crippa F Agresti R Donne VD Pascali C The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan Tumori 83 1997 542 543
24. Crippa F Agresti R Seregni E Greco M Prospective valuation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer J Nucl Med 39 1998 4 8
25. Bender H Kirst J Palmedo H Schomburg A Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma Anticancer Research 17 1997 1687 1692
26. Harris JR Morrow M Bonadonna G Cancer of the breast DeVita VT Hellman S Rosenberg SA Cancer: principles and practice of oncology 5th Ed 1997 Lippincott Philadelphia, PA 1557 1616
27. McCready DR Hortobagyi GN Kau SW Smith TL The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer Arch Surg 124 1988 21
28. Offodile R Hoh C Barksy SH Nelson SD Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled Dextran Cancer 82 1998 1704 1708
29. Alazraki NP Eshima D Eshima LA Herda SC Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers Sem Nucl Med 27 1997 55 67
30. Moon D Silverman D Maddahi J Glaspy J Accuracy of whole body FDG PET for the detection of recurrent or metastatic breast carcinoma J Nucl Med 39 1998 431 435
31. Mick R Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 13 1989 33 38
32. Wahl R Zasadny K Helvie M Hutchins G Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Onc 1993 1993 2101 2111
33. Jansson T Westlin J Ahlstom H Lilja A Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Onc 13 1995 1470 1477
34. Bruce DM Evans NT Heys SD Needham G Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers Eur J Surg Onc 21 1995 280 283
35. Bassa P Kim EE Inoue T Wong FCL Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer J Nucl Med 37 1996 931 938